Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing.

Abstract excerpt

Introduction We analyzed the outcomes of patients with advanced cancers in our institution treated with off-label drugs targeting actionable genomic alteration based on next-generation sequencing who did not qualify for clinical trials. Purposes Our study endpoint was objective tumor response or stable disease at 16 weeks or later after treatment initiation. Methods Sixteen patients were included, 8 treated with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to B7-H1 Antigen
• Share to Biomarkers, Tumor